Samiec M et al. |
Trichostatin A-mediated epigenetic transformation of adult bone marrow-derived mesenchymal stem cells biases the in vitro developmental capability, quality, and pluripotency extent of porcine cloned embryos. |
2015 |
Biomed Res Int |
pmid:25866813
|
Hou H et al. |
Influence of intra-articular administration of trichostatin a on autologous osteochondral transplantation in a rabbit model. |
2015 |
Biomed Res Int |
pmid:25866784
|
Chan ST et al. |
Oral and intraperitoneal administration of quercetin decreased lymphocyte DNA damage and plasma lipid peroxidation induced by TSA in vivo. |
2014 |
Biomed Res Int |
pmid:24868531
|
Florea AM |
DNA methylation pyrosequencing assay is applicable for the assessment of epigenetic active environmental or clinical relevant chemicals. |
2013 |
Biomed Res Int |
pmid:24093099
|
Ilicic M et al. |
Modulation of Progesterone Receptor Isoform Expression in Pregnant Human Myometrium. |
2017 |
Biomed Res Int |
pmid:28540297
|
Piotrowska H and Jagodzinski PP |
Trichostatin A, sodium butyrate, and 5-aza-2'-deoxycytidine alter the expression of glucocorticoid receptor alpha and beta isoforms in Hut-78 T- and Raji B-lymphoma cell lines. |
2007 |
Biomed. Pharmacother. |
pmid:17498915
|
Drzewiecka H and Jagodzinski PP |
Trichostatin A reduced phospholipase C gamma-1 transcript and protein contents in MCF-7 breast cancer cells. |
2012 |
Biomed. Pharmacother. |
pmid:22257695
|
Cheng SP et al. |
Regulation of leptin receptor expression in human papillary thyroid cancer cells. |
2012 |
Biomed. Pharmacother. |
pmid:22560341
|
Åuczak MW and JagodziÅ„ski PP |
Trichostatin A down-regulates CYP19 transcript and protein levels in MCF-7 breast cancer cells. |
2009 |
Biomed. Pharmacother. |
pmid:18602794
|
Feng W et al. |
Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cyclinB1/Cdk1 in pancreatic cancer cells. |
2015 |
Biomed. Pharmacother. |
pmid:26349994
|
Sobolewski C et al. |
Histone Deacetylase Inhibitors Activate Tristetraprolin Expression through Induction of Early Growth Response Protein 1 (EGR1) in Colorectal Cancer Cells. |
2015 |
Biomolecules |
pmid:26343742
|
McCulloch MW et al. |
Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives. |
2009 |
Bioorg. Med. Chem. |
pmid:19022675
|
Fu J et al. |
Discovery of 1H-benzo[d][1,2,3]triazol-1-yl 3,4,5-trimethoxybenzoate as a potential antiproliferative agent by inhibiting histone deacetylase. |
2010 |
Bioorg. Med. Chem. |
pmid:21067930
|
Saha A et al. |
Synthesis and biological evaluation of a targeted DNA-binding transcriptional activator with HDAC8 inhibitory activity. |
2013 |
Bioorg. Med. Chem. |
pmid:23719282
|
Schäfer S et al. |
Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs). |
2008 |
Bioorg. Med. Chem. |
pmid:18054239
|
Terracciano S et al. |
Synthesis and biological activity of cyclotetrapeptide analogues of the natural HDAC inhibitor FR235222. |
2010 |
Bioorg. Med. Chem. |
pmid:20381359
|
Chen PC et al. |
Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group. |
2008 |
Bioorg. Med. Chem. |
pmid:18397827
|
Whitehead L et al. |
Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors. |
2011 |
Bioorg. Med. Chem. |
pmid:21723733
|
Feng T et al. |
Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2). |
2013 |
Bioorg. Med. Chem. |
pmid:23820574
|
Mukherjee P et al. |
Structural insights into the Plasmodium falciparum histone deacetylase 1 (PfHDAC-1): A novel target for the development of antimalarial therapy. |
2008 |
Bioorg. Med. Chem. |
pmid:18362073
|
Di Micco S et al. |
Structural basis for the design and synthesis of selective HDAC inhibitors. |
2013 |
Bioorg. Med. Chem. |
pmid:23693069
|
Patil V et al. |
Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group. |
2010 |
Bioorg. Med. Chem. |
pmid:19914074
|
Nishino N et al. |
Interaction of aliphatic cap group in inhibition of histone deacetylases by cyclic tetrapeptides. |
2008 |
Bioorg. Med. Chem. |
pmid:17900911
|
Shivashimpi GM et al. |
Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. |
2007 |
Bioorg. Med. Chem. |
pmid:17881232
|
Estiu G et al. |
On the inhibition of histone deacetylase 8. |
2010 |
Bioorg. Med. Chem. |
pmid:20472442
|
Kaldre D et al. |
Optimization of histone deacetylase inhibitor activity in non-secosteroidal vitamin D-receptor agonist hybrids. |
2015 |
Bioorg. Med. Chem. |
pmid:26048026
|
Kiyokawa S et al. |
New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group. |
2010 |
Bioorg. Med. Chem. |
pmid:20452226
|
Nishino N et al. |
Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand. |
2004 |
Bioorg. Med. Chem. Lett. |
pmid:15109626
|
Marson CM et al. |
Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. |
2004 |
Bioorg. Med. Chem. Lett. |
pmid:15109636
|
Vaisburg A et al. |
(2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors. |
2004 |
Bioorg. Med. Chem. Lett. |
pmid:14684344
|
Hoque MA et al. |
Cyclic tetrapeptides with thioacetate tails or intramolecular disulfide bridge as potent inhibitors of histone deacetylases. |
2012 |
Bioorg. Med. Chem. Lett. |
pmid:23021104
|
Krennhrubec K et al. |
Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. |
2007 |
Bioorg. Med. Chem. Lett. |
pmid:17346959
|
Rajak H et al. |
2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors. |
2011 |
Bioorg. Med. Chem. Lett. |
pmid:21875796
|
Vaidya AS et al. |
Novel histone deacetylase 8 ligands without a zinc chelating group: exploring an 'upside-down' binding pose. |
2012 |
Bioorg. Med. Chem. Lett. |
pmid:23010266
|
Loudni L et al. |
Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors. |
2007 |
Bioorg. Med. Chem. Lett. |
pmid:17624773
|
Hirata Y et al. |
Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain. |
2012 |
Bioorg. Med. Chem. Lett. |
pmid:22321215
|
Jose B et al. |
Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. |
2004 |
Bioorg. Med. Chem. Lett. |
pmid:15454224
|
Liao V et al. |
Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects. |
2012 |
Bioorg. Med. Chem. Lett. |
pmid:22932316
|
Smil DV et al. |
Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors. |
2009 |
Bioorg. Med. Chem. Lett. |
pmid:19111466
|
Islam NM et al. |
Bicyclic peptides as potent inhibitors of histone deacetylases: optimization of alkyl loop length. |
2010 |
Bioorg. Med. Chem. Lett. |
pmid:20045316
|
Riester D et al. |
Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases. |
2009 |
Bioorg. Med. Chem. Lett. |
pmid:19457659
|
Uesato S et al. |
Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group. |
2002 |
Bioorg. Med. Chem. Lett. |
pmid:11992774
|
Hooven LA et al. |
Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells. |
2005 |
Bioorg. Med. Chem. Lett. |
pmid:15713371
|
Chen B et al. |
Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. |
2005 |
Bioorg. Med. Chem. Lett. |
pmid:15713393
|
Yu D et al. |
Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression. |
2011 |
Bioorg. Med. Chem. Lett. |
pmid:21840716
|
Choi E et al. |
Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors. |
2011 |
Bioorg. Med. Chem. Lett. |
pmid:21256006
|
Nakao Y et al. |
Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. |
2008 |
Bioorg. Med. Chem. Lett. |
pmid:18397826
|
Mazitschek R et al. |
Development of a fluorescence polarization based assay for histone deacetylase ligand discovery. |
2008 |
Bioorg. Med. Chem. Lett. |
pmid:18430569
|
Charrier C et al. |
Synthesis of rigid trichostatin A analogs as HDAC inhibitors. |
2006 |
Bioorg. Med. Chem. Lett. |
pmid:16904890
|
Lavoie R et al. |
Design and synthesis of a novel class of histone deacetylase inhibitors. |
2001 |
Bioorg. Med. Chem. Lett. |
pmid:11597413
|